Drugs that contain Opicapone
1. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(3 years from now) | |
| US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(4 years from now) | |
| US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(2 years from now) | |
| US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(3 years from now) | |
| US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(5 years from now) | |
| US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL
More Information on Dosage
ONGENTYS family patents
